Company registration number 02907624 (England and Wales)
PHARMA HYGIENE PRODUCTS LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
PAGES FOR FILING WITH REGISTRAR
PHARMA HYGIENE PRODUCTS LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 9
PHARMA HYGIENE PRODUCTS LIMITED
BALANCE SHEET
AS AT
30 SEPTEMBER 2025
30 September 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
3,900
5,850
Tangible assets
4
5,810
6,219
Investments
5
-
0
1
9,710
12,070
Current assets
Stocks
255,612
218,637
Debtors
6
260,594
233,187
Cash at bank and in hand
31,831
22,683
548,037
474,507
Creditors: amounts falling due within one year
7
(290,431)
(222,629)
Net current assets
257,606
251,878
Total assets less current liabilities
267,316
263,948
Provisions for liabilities
1,328
(1,555)
Net assets
268,644
262,393
Capital and reserves
Called up share capital
8
11,000
11,000
Share premium account
15,800
15,800
Profit and loss reserves
241,844
235,593
Total equity
268,644
262,393

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 26 June 2026 and are signed on its behalf by:
S B Holroyd
Director
Company registration number 02907624 (England and Wales)
PHARMA HYGIENE PRODUCTS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 2 -
1
Accounting policies
Company information

Pharma Hygiene Products Limited is a private company limited by shares incorporated in England and Wales. The registered office is Olympus House, Mill Green Road, Haywards Heath, West Sussex, RH16 1XQ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the company as an individual entity and not about its group.

1.2
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years.

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

PHARMA HYGIENE PRODUCTS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 3 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
Fixtures and fittings
33.33% on a reducing balance basis

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

PHARMA HYGIENE PRODUCTS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 4 -
1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.8
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

PHARMA HYGIENE PRODUCTS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 5 -
1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

PHARMA HYGIENE PRODUCTS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 6 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
7
7
3
Intangible fixed assets
Goodwill
£
Cost
At 1 October 2024 and 30 September 2025
19,500
Amortisation and impairment
At 1 October 2024
13,650
Amortisation charged for the year
1,950
At 30 September 2025
15,600
Carrying amount
At 30 September 2025
3,900
At 30 September 2024
5,850

On 1 August 2018 the company acquired the trade and assets of Pharma Hygiene Products Limited for £15,000 together with legal costs of £4,500. The goodwill on the acquisition of the business was £19,500 and is being amortised over 10 years. Subsequent to the acquisition the company changed its name to Pharma Hygiene Products Limited.

PHARMA HYGIENE PRODUCTS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 7 -
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 October 2024
38,141
Additions
1,806
At 30 September 2025
39,947
Depreciation and impairment
At 1 October 2024
31,922
Depreciation charged in the year
2,215
At 30 September 2025
34,137
Carrying amount
At 30 September 2025
5,810
At 30 September 2024
6,219
5
Fixed asset investments
2025
2024
£
£
Shares in group undertakings and participating interests
-
0
1
Movements in fixed asset investments
Shares in subsidiaries
£
Cost or valuation
At 1 October 2024
1
Disposals
(1)
At 30 September 2025
-
Carrying amount
At 30 September 2025
-
At 30 September 2024
1

During the year, the company disposed of its £1 ordinary shareholding in a fellow group company to its parent undertaking for £1 as part of a group reorganisation. The transaction resulted in no gain or loss and there were no amounts outstanding at the year end.

PHARMA HYGIENE PRODUCTS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 8 -
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
53,030
94,570
Amounts owed by group undertakings
202,830
99,971
Other debtors
4,734
3,646
260,594
198,187
2025
2024
Amounts falling due after more than one year:
£
£
Amounts owed by group undertakings
-
0
35,000
Total debtors
260,594
233,187
7
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans and overdrafts
169,819
112,437
Trade creditors
31,372
24,881
Amounts owed to group undertakings
53,080
13,004
Corporation tax
2,521
7,452
Other taxation and social security
11,177
34,137
Other creditors
22,462
30,718
290,431
222,629

The company has given a multilateral guarantee, secured on the assets of the company, in respect of bank loans and overdrafts of group companies. At the balance sheet date the company had a contingent liability in respect of such bank loans and overdrafts of £1,223,606 (2024: £1,131,901).

8
Called up share capital
2025
2024
£
£
Ordinary share capital
Issued and fully paid
6,000 Fully paid Ordinary A shares of £1 each
6,000
6,000
5,000 Fully paid Ordinary B shares of £1 each
5,000
5,000
11,000
11,000

The Ordinary A and B shares of £1 each rank pari passu with the exception that the Ordinary B shares have no voting rights.

PHARMA HYGIENE PRODUCTS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 9 -
9
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 30 September 2025 and of its profit for the year then ended;

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- have been prepared in accordance with the requirements of the Companies Act 2006.

Senior Statutory Auditor:
Matthew Eade
Statutory Auditor:
BGM Helmores Limited
Date of audit report:
26 June 2026
10
Related party transactions

The company has taken advantage of the exemptions available under Financial Reporting Standard 102 not to disclose any transactions or balances with entities which are 100% controlled by the entity or its parent company, Adelphi Holdings Limited.

11
Parent company

The company is under the control of Adelphi Holdings Limited, a company registered in England and Wales. The ultimate controlling parties at the year end are Mrs A C Holroyd and Mr S B Holroyd.

Adelphi Holdings Limited holds 100% of the Ordinary share capital and 100% of the voting rights of the company. Adelphi Holdings Limited is the only group in which the results of that Company and its subsidiaries are consolidated. Copies of the financial statements of Adelphi Holdings Limited may be obtained from the company's registered office.

2025-09-30 2024-10-01 false false false 26 June 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity J W Hart S B Holroyd D J Willis C J Wilson A C Holroyd 02907624 2024-10-01 2025-09-30 02907624 2025-09-30 02907624 2024-09-30 02907624 core:NetGoodwill 2025-09-30 02907624 core:NetGoodwill 2024-09-30 02907624 core:OtherPropertyPlantEquipment 2025-09-30 02907624 core:OtherPropertyPlantEquipment 2024-09-30 02907624 core:CurrentFinancialInstruments core:WithinOneYear 2025-09-30 02907624 core:CurrentFinancialInstruments core:WithinOneYear 2024-09-30 02907624 core:CurrentFinancialInstruments 2025-09-30 02907624 core:CurrentFinancialInstruments 2024-09-30 02907624 core:ShareCapital 2025-09-30 02907624 core:ShareCapital 2024-09-30 02907624 core:SharePremium 2025-09-30 02907624 core:SharePremium 2024-09-30 02907624 core:RetainedEarningsAccumulatedLosses 2025-09-30 02907624 core:RetainedEarningsAccumulatedLosses 2024-09-30 02907624 core:ShareCapitalOrdinaryShareClass1 2025-09-30 02907624 core:ShareCapitalOrdinaryShareClass1 2024-09-30 02907624 core:ShareCapitalOrdinaryShareClass2 2025-09-30 02907624 core:ShareCapitalOrdinaryShareClass2 2024-09-30 02907624 core:ShareCapitalOrdinaryShares 2025-09-30 02907624 core:ShareCapitalOrdinaryShares 2024-09-30 02907624 bus:Director2 2024-10-01 2025-09-30 02907624 core:Goodwill 2024-10-01 2025-09-30 02907624 core:FurnitureFittings 2024-10-01 2025-09-30 02907624 2023-10-01 2024-09-30 02907624 core:NetGoodwill 2024-09-30 02907624 core:NetGoodwill 2024-10-01 2025-09-30 02907624 core:OtherPropertyPlantEquipment 2024-09-30 02907624 core:OtherPropertyPlantEquipment 2024-10-01 2025-09-30 02907624 core:Non-currentFinancialInstruments 2025-09-30 02907624 core:Non-currentFinancialInstruments 2024-09-30 02907624 bus:OrdinaryShareClass1 2024-10-01 2025-09-30 02907624 bus:OrdinaryShareClass2 2024-10-01 2025-09-30 02907624 bus:OrdinaryShareClass1 2025-09-30 02907624 bus:OrdinaryShareClass2 2025-09-30 02907624 bus:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 02907624 bus:FRS102 2024-10-01 2025-09-30 02907624 bus:Audited 2024-10-01 2025-09-30 02907624 bus:Director1 2024-10-01 2025-09-30 02907624 bus:Director3 2024-10-01 2025-09-30 02907624 bus:Director4 2024-10-01 2025-09-30 02907624 bus:CompanySecretary1 2024-10-01 2025-09-30 02907624 bus:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 02907624 bus:FullAccounts 2024-10-01 2025-09-30 xbrli:pure xbrli:shares iso4217:GBP